Vascular Biogenics Ltd. Banner Image

Vascular Biogenics Ltd.

  • Ticker VBLT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Vascular Biogenics Ltd. Logo Image
  • 11-50 Employees
  • Based in Modiin, Israel
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focusMore on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks.
Vascular Biogenics Ltd.

Most Recent Annual Report

Vascular Biogenics Ltd.
MOST RECENT 2021 Annual Report

Older/Archived Annual Reports